| Study Period | 2019 - 2030 |
| 2024 Market Size | USD 6,199.8 Million |
| 2025 Market Size | USD 7,142.2 Million |
| 2030 Forecast | USD 14,497.0 Million |
| Growth Rate (CAGR) | 15.2% |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Nature of the Market | Consolidated |
| Largest Distribution Channel Category | Hospital Pharmacy |
|
Explore the market potential with our data-driven report
The global human growth hormone market size is estimated at USD 6,199.8 million in 2024, and it is expected to grow at a CAGR of 15.2% during 2024–2030, reaching USD 14,497.0 Million by 2030. The pituitary gland produces this peptide hormone, which stimulates development in children and teenagers. Specific cellular differentiation aids in the formation of the skeletal system. The hormone affects carbohydrate metabolism, protein metabolism, and fat metabolism, in addition to increasing growth.
Furthermore, the use of associated medicines in patients deficient in it results in considerable improvements in the patient's functioning ability, mental clarity, and memory. Gigantism is caused by excessive growth hormone release, while dwarfism is caused by a lack of it. The recombinant DNA technology is used to design and produce such medications. Previously, these medicines were mostly employed as a replacement therapy in adult and pediatric patients with a growth hormone shortage.
In the near future, the market will be driven by the rising cases of hormonal diseases and the solid portfolios of pharma and biopharma companies across the globe.
Moreover, the market advance is likely to be fueled by an increase in the number of board approvals and launches of breakthrough therapies. For example, In January 2021, Pfizer and OPKO Health Inc. received the FDA approval for somatrogon, prescribed for the treatment of juvenile patients with growth hormone deficiency.
The market would also be driven by the increasing prevalence of illnesses such as Turner syndrome, Laron syndrome, and Noonan syndrome. Furthermore, several companies are extensively conducting R&D to create a growth hormone that has minimal side effects and can be a long-term solution. The market is also driven by the government and private sector efforts to raise awareness of growth hormone deficiency.
The short-acting category is the larger, with a share of 65% in 2024. The use cases of SAGHs are well-established, and this variant has been known for a longer time than its long-acting counterpart. Moreover, acting over short durations, this variant needs to be administered more frequently, which makes is a more-repetitive purchase. Additionally, more patented and generic variants of SAGHs are available compared to LAGHs.
LAGHs will account for the higher CAGR, of 15.5%, during 2024–2030. In many countries, daily recombinant HGH is currently approved for adults and children with a growth hormone deficiency, as it has few side-effects. Daily injections, on the other hand, can be uncomfortable and stressful for certain patients, thus leading to non-adherence and poor treatment results. This has led to the development of a number of LAGH therapies, which allow for a lower injection frequency, such as weekly, bi-weekly, or monthly. These analogs could potentially improve patient acceptance, tolerance, and treatment versatility; thus, they will be preferred in the long run.
The following product types have been analyzed:
Turner syndrome accounts for the major market share, of 40%, in 2024. Turner syndrome is a female-specific chromosomal disease characterized by the deletion of one of the X chromosomes, either partially or completely. Symptoms include a receding or indistinct hairline and a wide neck, as well as a high blood pressure, mild eye difficulties, sagging eyelids, and an underactive thyroid gland. Turner syndrome affects about 1 in every 2,000–2,500 newly born females. It is estimated to influence around 70,000 females in the U.S.
Turner syndrome patients are more likely to contract the COVID-19 virus, which can cause serious sickness. They are also more likely to have congenital heart problems, such as a bicuspid aortic valve. Further, COVID-19 can cause significant consequences if there is an underlying medical issue, such as heart disease. Because Turner syndrome is linked to a slew of health difficulties, including heart disease, autoimmune illnesses, mental health issues, infertility, and hearing loss, pregnancy complications, apart from COVID-19, the demand for growth hormone treatments is rising.
Small for gestational age is the fastest-growing category, over this decade. This is attributed to the increasing awareness of this condition and its early diagnosis in children. Up to 15% of the children born around the world are small for gestational age, and many continue to show stunted growth even after the age of 3.
The report offers insights into the below-mentioned indications:
Hospital pharmacies account for the major market share, in 2024. This was due to the preference for synthetic or recombinant variants of this hormone and the ease with which it is available at hospital pharmacies. In addition, the rising awareness of growth hormone shortage, as well as the increasing volume of hospital visits for treatment, is predicted to propel the hospital pharmacy distribution channel sector forward.
Online pharmacies will have the highest CAGR during the forecast period, of 15.5%. This is attributed to the increasing popularity of e-commerce and growing trust in online pharmacies, which now ask for a signed doctor’s prescription before delivering medications. Online shopping has many well-known benefits, including promotional offers and discounts, detailed information on similar products of different brands, electronic payments, and doorstep delivery. Moreover, the COVID-19 pandemic has heightened people’s interest in avoiding the long queues at physical stores and shopping via their laptops and smartphones instead.
We have studied the following distribution channels:
Drive strategic growth with comprehensive market analysis
The regional breakdown of the market is as follows:
The market is moderately consolidated with few market players holding significant market shares. Moreover, there have been several strategic developments for more-effective and long-lasting medications. The number of pipeline pharmaceuticals is growing due to the increasing R&D for viable therapies. Hence, many companies are working on creating new and advanced drugs to combat the competition in the market.
Want a report tailored exactly to your business need?
Request Customization
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages